

For immediate release

9 April 2025



ALLIANCE PHARMA PLC
("Alliance" or the "Group")

Publication of Annual Report and Accounts

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Annual Report & Accounts for the year ended 31 December 2024 was published and made available today, 9 April 2025, on the Group's website: www.alliancepharmaceuticals.com.

A printed copy of the annual report is available on request by contacting Burson Buchanan by email at alliancepharma@buchanan.uk.com or by telephoning 020 7466 5000.

For further information:

Alliance Pharma plc

Head of Investor Relations & Corporate Communications:
Cora McCallum
ir@allianceph.com

+ 44 (0)1249 466966

+ 44 (0)1249 705168

Burson Buchanan

Mark Court / Sophie Wills
alliancepharma@buchanan.uk.com

+ 44 (0)20 7466 5000

Deutsche Numis (Nominated Adviser and Joint Broker)

Freddie Barnfield / Duncan Monteith / Sher Shah

+ 44 (0)20 7260 1000

Investec Bank plc (Joint Broker)

Patrick Robb / Maria Gomez de Olea

+ 44 (0) 20 7597 5970

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

